In vivo anti-CTLA-4 treatment increases the frequency of neo-antigen specific tumor-infiltrating T cells in other responsive murine cancer lines, suggesting that clonal expansion of T cells, and reduction in tumor TCR diversity is a feature that accompanies anti-CTLA-4 treatment (63, 64). The gene discussed is CTLA4; the disease is cancer.